Hong Kong Stock Movers: LEPU BIO Surges Nearly 4% After Positive Topline Results from Global Phase III CMG901 Trial

Stock News

Jul 28

LEPU BIO (02157) shares climbed nearly 4% in early trading, briefly surging over 12%. As of press time, the stock was up 3.83% at HK$4.61, with turnover reaching HK$91.6484 million.

On July 28, the company announced an update on its collaboration with AstraZeneca AB, a global biopharmaceutical firm, regarding the antibody-drug conjugate (ADC) candidate CMG901 (sonesitatug vedotin, also known as AZD0901).

In February 2023, KYM Biosciences Inc. (KYM), a joint venture established by the company and Konos Biopharma, entered into a global exclusive license agreement with AstraZeneca to develop and commercialize CMG901. As of the announcement date, positive topline results from the global Phase III CLARITY-Gastric01 trial showed that sonesitatug vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to the investigator's choice of treatment in patients with 2L+ Claudin 18.2-positive advanced gastric cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1155595300"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155595300\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155595300?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 15:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155595300","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movers: LEPU BIO Surges Nearly 4% After Positive Topline Results from Global Phase III CMG901 Trial","media":"Stock News","content":"<p><b>LEPU BIO</b> (<b>02157</b>) shares climbed nearly 4% in early trading, briefly surging over 12%. As of press time, the stock was up 3.83% at HK$4.61, with turnover reaching HK$91.6484 million.<br><br>On July 28, the company announced an update on its collaboration with AstraZeneca AB, a global biopharmaceutical firm, regarding the antibody-drug conjugate (ADC) candidate CMG901 (sonesitatug vedotin, also known as AZD0901).<br><br>In February 2023, KYM Biosciences Inc. (KYM), a joint venture established by the company and Konos Biopharma, entered into a global exclusive license agreement with AstraZeneca to develop and commercialize CMG901. As of the announcement date, positive topline results from the global Phase III CLARITY-Gastric01 trial showed that sonesitatug vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to the investigator's choice of treatment in patients with 2L+ Claudin 18.2-positive advanced gastric cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movers: LEPU BIO Surges Nearly 4% After Positive Topline Results from Global Phase III CMG901 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movers: LEPU BIO Surges Nearly 4% After Positive Topline Results from Global Phase III CMG901 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-28 15:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>LEPU BIO</b> (<b>02157</b>) shares climbed nearly 4% in early trading, briefly surging over 12%. As of press time, the stock was up 3.83% at HK$4.61, with turnover reaching HK$91.6484 million.<br><br>On July 28, the company announced an update on its collaboration with AstraZeneca AB, a global biopharmaceutical firm, regarding the antibody-drug conjugate (ADC) candidate CMG901 (sonesitatug vedotin, also known as AZD0901).<br><br>In February 2023, KYM Biosciences Inc. (KYM), a joint venture established by the company and Konos Biopharma, entered into a global exclusive license agreement with AstraZeneca to develop and commercialize CMG901. As of the announcement date, positive topline results from the global Phase III CLARITY-Gastric01 trial showed that sonesitatug vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to the investigator's choice of treatment in patients with 2L+ Claudin 18.2-positive advanced gastric cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBBJ","symbol_name":"Defiance Nasdaq Junior Biotechnology ETF","start_time":0,"source_url":"","article_id":"1155595300","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155595300","pubTimestamp":1785224086,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEPU BIO (02157) shares climbed nearly 4% in early trading, briefly surging over 12%. As of press time, the stock was up 3.83% at HK$4.61, with turnover reaching HK$91.6484 million.On July 28, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","PSYK":"PSYK ETF","02157":"乐普生物","BK4134":"信息科技咨询与其它服务","MDTX":"Corgi MediaTek 2x Daily ETF","BK1161":"生物科技","IBBQ":"Invesco Nasdaq Biotechnology ETF","VXUS":"国际股票ETF-Vanguard","BK4588":"碎股","III":"信息服务","KCAI":"KraneShares China Alpha Index ETF","BK4585":"ETF&股票定投概念","BMED":"iShares Health Innovation Active ETF"},"translate_title":"港股推动者：全球 III 期 CMG901 试验取得积极营收结果后，乐普生物股价飙升近 4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBQ":1,"III":1,"VXUS":1,"KCAI":1,"IBBJ":1,"PSYK":1,"02157":1,"MDTX":1,"BMED":1},"content_text":"LEPU BIO (02157) shares climbed nearly 4% in early trading, briefly surging over 12%. As of press time, the stock was up 3.83% at HK$4.61, with turnover reaching HK$91.6484 million.On July 28, the company announced an update on its collaboration with AstraZeneca AB, a global biopharmaceutical firm, regarding the antibody-drug conjugate (ADC) candidate CMG901 (sonesitatug vedotin, also known as AZD0901).In February 2023, KYM Biosciences Inc. (KYM), a joint venture established by the company and Konos Biopharma, entered into a global exclusive license agreement with AstraZeneca to develop and commercialize CMG901. As of the announcement date, positive topline results from the global Phase III CLARITY-Gastric01 trial showed that sonesitatug vedotin demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to the investigator's choice of treatment in patients with 2L+ Claudin 18.2-positive advanced gastric cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}